Enlarge image
Ozempic preparation: massive demand
Photo: George Frey / REUTERS
The skyrocketing demand for weight loss injections and other similar medications is giving the entire Danish economy a boost.
This is reported by the QZ portal, citing financial forecasts.
The country's largest bank, Danske Bank, predicts that Denmark's gross domestic product will grow by 2.1 percent in 2024.
This is largely due to Novo Nordisk, the manufacturer of the diabetes drug Ozempic and the weight loss drug Wegovy.
“The Danish economy has developed much better than expected after high inflation and massive interest rate increases,” said a press release from the bank.
The main reason is “the success of the pharmaceutical giant Novo Nordisk”.
The company's success had already helped Denmark avert a GDP decline in 2023.
At that time, Denmark's GDP grew by 1.8 percent.
Novo Nordisk reported a 31 percent increase in sales for 2023 to 232.3 billion Danish crowns, the equivalent of around 33.8 billion dollars.
For 2024, the company expects a further increase in sales of up to 26 percent.
The demand for the weight loss injections has now made Novo Nordisk the most valuable company in Europe.
ssu